First Horizon Advisors, Inc. Dyne Therapeutics, Inc. Transaction History
First Horizon Advisors, Inc.
- $3.28 Billion
- Q2 2024
A detailed history of First Horizon Advisors, Inc. transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, First Horizon Advisors, Inc. holds 153 shares of DYN stock, worth $4,560. This represents 0.0% of its overall portfolio holdings.
Number of Shares
153Holding current value
$4,560% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding DYN
# of Institutions
203Shares Held
105MCall Options Held
82.7KPut Options Held
24.8K-
Atlas Venture Life Science Advisors, LLC8.02MShares$239 Million37.7% of portfolio
-
Fcpm Iii Services B.V. Naarden, P77.85MShares$234 Million40.83% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$220 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY6.39MShares$190 Million3.76% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$180 Million3.22% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $1.54B
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...